We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Prognostic Value of Blood Cell Counts Investigated

By LabMedica International staff writers
Posted on 29 Oct 2018
Print article
Image: A blood smear showing various leukocytes used to assess the complete white blood cell count by microscopy (Photo courtesy of the University of Minnesota).
Image: A blood smear showing various leukocytes used to assess the complete white blood cell count by microscopy (Photo courtesy of the University of Minnesota).
The prognosis and treatment of gastric cancer patients after radical gastrectomy mainly depends on classification of malignant tumors (TNM) stage system. However, the prognosis of gastric cancer patients could be various even with the same tumor stage.

Over the past decades, prognostic value of blood test parameters in gastric cancer patients has been investigated by numerous studies, because a blood test is simple, convenient, reproducible and cost-effective. However, the most common parameters been investigated in the previous reports were neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).

Medical scientists at the Fourth Military Medical University (Xi’an, China) enrolled a total of 3,243 gastric cancer patients from September 2008 to March 2015. There were 2,538 male and 705 female and the median age was 58 years (range 20–90). The median follow-up time was 24.9 months (range 1–75). All patients were treated with radical D2 gastrectomy, defined as a dissection of all the Group 1 and Group 2 nodes, and regular follow up.

Preoperative blood test was performed within seven days before surgery. Absolute count of white blood cells or leukocytes (WBC), neutrophil, lymphocyte, monocyte and platelet were recorded. Patients with signs of infection were excluded. Clinicopathological data including gender, age, tumor location, tumor size, pathological type, tumor depth, lymph node metastasis and tumor stage were collected. The patients were followed up until November 2015 every three months.

The team reported that the statistically significant optimal cut off value was 6.19 × 109/L for WBC, 4.19 × 109/L for neutrophils, 1.72 × 109/L for lymphocytes, 0.51 × 109/L for monocytes, and 260 × 109/L for platelets, respectively. Neutrophil, lymphocyte, monocyte and platelet were risk factors for the prognosis of gastric cancer. However, only lymphocyte and monocyte were independent risk factors. Combination of lymphocyte and monocyte counts could increase the prognostic value for gastric cancer patients, especially in stage II/III gastric cancer patients.

The authors concluded that absolute count of blood cells was more convenient in predicting the prognosis of gastric cancer patients. High absolute count of neutrophil, monocyte and platelet, and low absolute count of lymphocyte were associated with poor prognosis of gastric cancer. However, only lymphocyte and monocyte count were independent prognostic predictors. The study was published on October 11, 2018, in the journal BMC Gastroenterology.

Related Links:
Fourth Military Medical University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.